Tenaya Therapeutics, Inc. files 10-K

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies and small molecule treatments for heart disease. The company reported a net loss of $90.6 million for the year ended December 31, 2025, an improvement from a net loss of $111.1 million in 2024, and anticipates needing substantial additional funding to complete product development and commercialization.